Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2020
|
| Subjects: | |
| Online Access: | https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|